Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease.
Mariana M ClavéNair Y MaedaAna M ThomazSergio P BydlowskiAntonio Augusto LopesPublished in: Congenital heart disease (2018)
In PAH associated with congenital heart disease, phosphodiesterase 5 inhibitors seem to have beneficial actions at microcirculatory level, beyond the proposed effects as vasodilators.